Top

Published in:

Open Access 01-12-2021 | Epstein-Barr Virus | Review

The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis

Authors: Weixing Liu, Gui Chen, Xin Gong, Yingqi Wang, Yaoming Zheng, Xiao Liao, Wenjing Liao, Lijuan Song, Jun Xu, Xiaowen Zhang

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

Numerous individual studies have investigated the diagnostic value of EBV-DNA, EA-IgA, VCA-IgA, EBNA1-IgA and Rta-IgG detection for nasopharyngeal carcinoma (NPC), but the conclusions remain controversial. This meta-analysis aimed to determine the value of EBV-DNA, EA-IgA, VCA-IgA, EBNA1-IgA and Rta-IgG detection in the diagnosis of NPC.

Methods

PROSPERO registration number: CRD42019145532. PubMed, EMBASE, Cochrane Library, and Chinese data libraries (Wanfang, CNKI, and CBM) were searched up to January 2019. The pooled sensitivity, specificity, and positive likelihood, negative likelihood, and diagnostic odds ratios were conducted in this meta-analysis. Summary receiver operating characteristic curves evaluated the test-performance global summary. Publication bias was examined by Deek’s funnel plot asymmetry test.

Results

Forty-seven studies with 8382 NPC patients (NPC group) and 15,089 individuals without NPC (Control group) were included in this meta-analysis. The sensitivity, specificity, positive likelihood (+ LR), negative likelihood (-LR), DOR and AUC of EBV-DNA in diagnosis of NPC were: 0.76 (95% CI 0.73–0.77), 0.96 (95% CI 0.95–0.97), 14.66 (95% CI 9.97–21.55), 0.19 (95% CI 0.13–0.28), 84 (95% CI 50.45–139.88), 0.96 (SE: 0.001), and 0.55 (95% CI 0.54–0.57), 0.96 (95% CI 0.96–0.97), 12.91 (95% CI 9.55–17.45), 0.35 (95% CI 0.29–0.43), 39.57 (95% CI 26.44–59.23), 0.94 (SE: 0.002) for the EA-IgA, and 0.85 (95% CI 0.84–0.85), 0.89 (95% CI 0.88–0.89), 6.73 (95% CI5.38–8.43), 0.17 (95% CI 0.12–0.23), 43.03 (95% CI 31.51–58.76), 0.93 (SE: 0.007) for the VCA-IgA, and 0.86 (95% CI 0.85–0.88), 0.87 (95% CI 0.88–0.90), 7.55 (95% CI 5.79–9.87), 0.16 (95% CI 0.13–0.19), 50.95 (95% CI 34.35–75.57), 0.94 (SE: 0.008) for the EBNA1-IgA, and 0.70 (95% CI 0.69–0.71), 0.94 (95% CI 0.94–0.95), 9.84 (95% CI 8.40–11.54), 0.25 (95% CI 0.21–0.31), 40.59 (95% CI 32.09–51.35), 0.95 (SE: 0.005) for the Rta-IgG. The EBV-DNA had larger AUC compared with other EBV-based antibodies (P < 0.05), while the difference between EA-IgA, VCA-IgA, EBNA1-IgA and Rta-IgG was not statistically significant (P > 0.05).

Conclusions

EBV-DNA, VCA-IgA, EBNA1-IgA and Rta-IgG detection have high accuracy in early diagnosis NPC. In addition, EBV-DNA detection has the higher diagnosis accuracy in NPC. On the other hand, EA-IgA is suitable for the diagnosis but not NPC screening.

Available only for authorised users

Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):90. https://doi.org/10.1186/s40880-017-0257-9.CrossRefPubMedPubMedCentral

Chan KCA, Woo JKS, King A, et al. Analysis of plasma epstein-barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513–22. https://doi.org/10.1056/NEJMoa1701717.CrossRefPubMed

Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356–64. https://doi.org/10.1200/JCO.2015.60.9347.CrossRefPubMed

Kosvyra A, Maramis C, Chouvarda I. Developing an integrated genomic profile for cancer patients with the use of NGS data. Emerging Sci J. 2019;3:157–67. https://doi.org/10.28991/esj-2019-01178.CrossRef

Lam WKJ, Chan JYK. Recent advances in the management of nasopharyngeal carcinoma. F1000Res. 2018;7:F1000 Faculty Rev-1829. https://doi.org/10.12688/f1000research.15066.1.CrossRefPubMedPubMedCentral

Chen Y, Chan ATC, Le Q, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64–80. https://doi.org/10.1016/S0140-6736(19)30956-0.CrossRefPubMed

McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388–96. https://doi.org/10.1001/jama.2017.19163.CrossRefPubMed

Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009.CrossRefPubMed

Walter Devillé L, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;9(2):1–13. https://doi.org/10.1186/1471-2288-2-9.CrossRef

10.

Jaeschke R, Guyatt GH, Sackett DL. Users’ guides to the medical literature III How to use an article about a diagnostic test B What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. 1994;271(9):703–7. https://doi.org/10.1001/jama.271.9.703.CrossRefPubMed

11.

Deeks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323(7305):157–62. https://doi.org/10.1136/bmj.323.7305.157.CrossRefPubMedPubMedCentral

12.

Huang P, Sun Y, Chen Y, Wang P, Shen Y. Clinical significance of EA-IgA antibody detection in Nasopharyngeal Carcinoma patients. J Fujian Med Coll. 1988;1:16–8.

13.

Mai S, Zong Y, Zhang M, Zhong B, Lin S. Detection of Epstein-Barr virus DNA in plasma/serum: a useful serological indicator for diagnosis of nasopharyngeal carcinoma. Chin Med J. 2002;115(12):1895–7. https://doi.org/10.3760/j.issn:0366-6999.2002.12.031.CrossRefPubMed

14.

Cheng W, Cheng G, Cheng H, Luo R. Assessment of nasopharyngeal carcinoma risk by EB virus antibody profile. Chin J Oncol. 2002;24(06):45–7. https://doi.org/10.1038/sj.cr.7290128.CrossRef

15.

Zhang C, Zong Y, Huang B, Sun Y, Ye Y, Feng K, et al. Enhancing the effciency of epstein-barr viral serologic test in the diagnosis of nasopharyngeal carcinoma. Chin J Oncol. 2002;24(04):356–9. https://doi.org/10.3760/j.issn:0253-3766.2002.04.013.CrossRef

16.

Gu Y, Zhang C, Ng S, Zong Y. Study on Sero-Diagnosis of Nasopharyngeal carcinoma using a dual antibody test against recombinant Epstein-Barr Virus Antigens. Chin J Clin Cancer. 2003;22(09):903–6. https://doi.org/10.3969/j.issn.1000-467X.2003.09.002.CrossRef

17.

Chan KH, Gu YL, Ng F, Ng PS, Seto WH, Sham JS, et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer. 2003;105(5):706–9. https://doi.org/10.1002/ijc.11130.CrossRefPubMed

18.

Shao J, Li Y, Gao H, Wu Q, Cui N, Zhang L, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004;100(6):1162–70. https://doi.org/10.1002/cncr.20099.CrossRefPubMed

19.

Leung SF. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-epstein-barr viral capsid antigen IgA Antibody. Clin Chem. 2004;50(2):339–45. https://doi.org/10.1373/clinchem.2003.022426.CrossRefPubMed

20.

Hu W, Zong Y, Li F. Comparison of six antibody assays detecting epstein-barr virus for serodiagnosis of nasopharyngeal carcinoma. Chin J Clin Oncol. 2006;33(14):795–8. https://doi.org/10.3969/j.issn.1000-8179.2006.14.005.CrossRef

21.

Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, et al. Single-assay combination of epstein-barr virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol. 2006;44(4):1459–67. https://doi.org/10.1128/JCM.44.4.1459-1467.2006.CrossRefPubMedPubMedCentral

22.

Zhu W, Liang Y, Zhang Y, et al. Applying EBV Rta-IgG in diagnosis of nasopharyngeal carcinoma. Chin J of Oncol Prev Treat. 2009;1(3):211–3. https://doi.org/10.3969/j.issn.1674-5671.2009.03.06.CrossRef

23.

Liang Y, Zong Y, Gu Y, Zhang Y, Feng Y, Liu Y, et al. Application of enzyme-linked immunosorbent assay to the serological diagnosis of nasopharyngeal carcinoma. J Pract Med. 2008;24(17):3055–8. https://doi.org/10.3969/j.issn.1006-5725.2008.17.063.CrossRef

24.

Sun J, Zheng A. Clinical significance of plasma EBV-DNA and VCA-IgA for nasopharyngeal carcinoma. J Modern Oncol. 2008;16(12):2086–7. https://doi.org/10.3969/j.issn.1672-4992.2008.12.016.CrossRef

25.

Chang K, Hsu C, Chang Y, Tsang N, Chen C, Lee T, et al. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol. 2008;44(8):784–92. https://doi.org/10.1016/j.oraloncology.2007.10.003.CrossRefPubMed

26.

Gu AD, Mo HY, Xie YB, et al. Evaluation of a multianalyte profiling assay and an enzyme-linked immunosorbent assay for serological examination of Epstein-Barr virus-specific antibody responses in diagnosis of nasopharyngeal carcinoma. Clin Vaccine Immunol. 2008;15(11):1684–8. https://doi.org/10.1128/CVI.00135-08.CrossRefPubMedPubMedCentral

27.

Zheng Y, Cai Y, Cheng J, Qing Y. Evaluation of detection of Epstein·Barr virus Rta/IgG in nasopharyngeal carcinoma. Chinese J Exp Clini Virol. 2009;23(4):285–7. https://doi.org/10.3760/cma.j.issn.1003-9279.2009.04.015.CrossRef

28.

Luo Y, Ou G, Chi P, Liang Y, Liu Y, Huang M. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma. Chin J Clin Cancer. 2009;28(1):96–9. https://doi.org/10.3321/j.issn:1000-467X.2009.01.019.CrossRef

29.

Jiang S, Liu Q. Application of logistic regression in combination with mutiple diagnostic tests for auxiliary diagnosis of nasopharyngeal carcinoma. Chin J Clin Cancer. 2009;2(28):213–6. https://doi.org/10.3321/j.issn:1000-467X.2009.02.020.CrossRef

30.

Deng Z. Value of detection of serum EBNAI -IGA and EBVCA -IgA by ELISA in diagnosis of nasopharyngeal carcinoma. China Tropical Med. 2009;9(9):1718–97.

31.

Kong P. The clinical value of the quantitative determination of EBV-DNA in blood serum and PBMC patients with nasopharyngeal carcinoma. J Shandong Med Coll. 2010;32(05):321–4. https://doi.org/10.14166/j.issn.1671-2420.2012.01.010CrossRef

32.

Sun J, Wang H, Xiao F, Liu Y. Clinical application of plasma cell free EBV-DNA serum CYFRA21-1 and VCA-IgA in patients with nasopharyngeal carcinoma. J Modern Oncol. 2010;18(10):1930–2. https://doi.org/10.3969/j.issn.1672-4992.2010.10.17.CrossRef

33.

Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, et al. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer. 2012;131(2):406–16. https://doi.org/10.1002/ijc.26380.CrossRefPubMed

34.

Liu W, Du K. Clinical significance of plasma Epstein-Bar virus DNA concentration in the diagnosis and treatment of nasopharyngeal carcinoma. Hainan Med J. 2012;23(18):7–9. https://doi.org/10.3969/j.issn.1003-6350.2012.18.003.CrossRef

35.

Zhu H, He X. Significance of detecting plasma EBV-DNA and VCA-IgA in patients with nasopharyngeal carcinoma. J Chinese Oncol. 2012;12(2):111–3.

36.

Wang ZJ, Cao WJ, Chen F, Jian S, Tang L, Wang S. Analysis of anti-Epstein-Barr virus antibody in patients with nasopharyngeal carcinoma in Shanghai. Chinese J Ophthalmol Otorhinolaryngol. 2012;12(1):40–6. https://doi.org/10.14166/j.issn.1671-2420.2012.01.010.CrossRef

37.

Ai P, Wang T, Zhang H, Wang Y, Song C, Zhang L, et al. Determination of antibodies directed at EBV proteins expressed in both latent and lytic cycles in nasopharyngeal carcinoma. Oral Oncol. 2013;49(4):326–31. https://doi.org/10.1016/j.oraloncology.2012.10.001.CrossRefPubMed

38.

Deng Z, Zhang Z. Relationship between EBVNAI-IgA and VCA-IgA antibodies with diagnosis and therapeutic effect of nasopharyngeal carcinoma. J Med Forum. 2011;32(19):108–14.

39.

Li Z, Wong YL. Quantitative detection of EBV-DNA for diagnosis of nasopharyngeal carcinoma. China Modern Med. 2013;20(14):106–7. https://doi.org/10.3969/j.issn.1674-4721.2013.14.052.CrossRef

40.

Li X, Chen Y, Zhen R, Pen W, Gao Y, Ye Q. The application value of Epstein-Barr virus Rta protein antibody IgG combined with two antibodies in the diagnosis and screening of nasopharyngeal carcinoma. Lab Med Clin. 2013;10(03):321–3. https://doi.org/10.3969/j.issn.1672-9455.2013.03.035.CrossRef

41.

Luo YL, Chen H, Peng SG, et al. Assessment of detection assays of Epstein-Barr viral Rta-lgG, VCA, lgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma. NatI Med J China. 2013;93(44):3516–9. https://doi.org/10.3760/cma.j.issn.0376-2491.2013.44.007.CrossRef

42.

Yan CE, Wang MJ, Jia DQ, et al. Diagnostic value of combined measurement of serum SA, EA-IgA, VCA-IgA and CgA levels in patients with nasopharyngeal carcinoma. Chinese J Med. 2013;48(10):27–8. https://doi.org/10.3969/j.issn.1008-1070.2013.10.010.CrossRef

43.

Tang GQ, Sa HF, Tang YZ. Detection of serum Epstein-Barr virus Rta-IgG applied to diagnosis of Nasopharyngeal carcinoma. Guangxi Med J. 2014;36(8):1083–5. https://doi.org/10.11675/j.issn.0253-4304.2014.08.20 .CrossRef

44.

Cai Y, Li J, Lu A, Zheng Y, Zhong W, Wang W, et al. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2014;15(5):2001–6. https://doi.org/10.7314/apjcp.2014.15.5.2001.CrossRefPubMed

45.

Peng YH, Xu YW, Huang LS, Zhai T, et al. Autoantibody signatures combined with Epstein-Barr virus capsid antigen-IgA as a biomarker panel for the detection of nasopharyngeal carcinoma. Cancer Prev Res. 2015;8(8):729–36. https://doi.org/10.1158/1940-6207.CAPR-14-0397.CrossRef

46.

Xu Q, Zheng SH, Lin SX. Clinical value of Rta protein antibody IgG of EB virus in diagnosis for nasopharynx cancer. Int J Lab Med. 2015;36(17):2500–1. https://doi.org/10.3969/j.issn.1673-4130.2015.17.019.CrossRef

47.

Xia C, Zhu K, Zheng G. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis. Int J Clin Exp Pathol. 2015;12(8):16104–10.

48.

Ye Q, Li X, Chen Y, Guo J. Diagnostic value of serological Epstein-Barr viral antibodies and Epstein-Barr viral DNA Assays in the management of nasopharyngeal carcinoma. Modern Oncol. 2016;19(24):3045–8. https://doi.org/10.3969/j.issn.1672-4992.2016.19.012.CrossRef

49.

Li RC, Du Y, Zeng QY, et al. Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma. Oncotarget. 2016;7(13):16372–83. https://doi.org/10.18632/oncotarget.7688.CrossRefPubMedPubMedCentral

50.

Yu X, Ji M, Cheng W, Huang Y, Li F. Assessment of EBV antibodies and EBV-DNA in the diagnosis and stages of nasopharyngeal carcinoma. Chin J Clin Oncol. 2016;43(15):650–4. https://doi.org/10.3969/j.issn.1000-8179.2016.15.393.CrossRef

51.

Li Y, Wang K, Yin SK, Zheng HL, Min DL. Expression of Epstein-Barr virus antibodies EA-IgG, Rta-IgG, and VCA-IgA in nasopharyngeal carcinoma and their use in a combined diagnostic assay. Genet Mol Res. 2016. https://doi.org/10.4238/gmr.15017368.CrossRefPubMed

52.

Zhao X, Zhang L, Quan C, et al. Clinical significance of EBV-BRLF1 gene and EBV-Rta/IgG antibody expression in nasopharyngeal carcinoma. Chin J Ophthalmol Otorhinolaryngol. 2016;16:243–7. https://doi.org/10.14166/j.issn.1671-2420.2016.04.004.CrossRef

53.

Gu X, Li Y, Lv R, Sheng H. The correlation between serum homocysteine and EB virus three antibodies in nasopharyngeal carcinoma and the evaluation of its diagnosis performance. Chin J Health Lab Tec. 2016;26(02):231–3.

54.

Guo J, Zhen Y, Chui Z, et al. Associations and interactions between EB virus infection and XRCC1 Arg399Gln polymorphism in nasopharyngeal carcinoma. Exp Lab Med. 2016;34(5):539–44. https://doi.org/10.3969/j.issn.1674-1129.2016.05.002.CrossRef

55.

Gao R, Wang L, Liu Q, Zhang L, Ye Y, et al. Evaluation of seven recombinant VCA-IgA ELISA kits for the diagnosis of nasopharyngeal carcinoma in China: a case–control trial. BMJ Open. 2017;7(6):e013211. https://doi.org/10.1136/bmjopen-2016-013211.CrossRefPubMedPubMedCentral

56.

Zhao M, Chen XH. Clinical value of serum EB virus gene, carcinoembryonic antigen and ferritin in diagnosis of nasopharyngeal carcinoma. Med Innovat China. 2018;15(23):134–7. https://doi.org/10.3969/j.issn.1674-4985.2018.23.035.CrossRef

57.

Yi XH, Lai HC, Liu JZ, Lin SC, et al. The combined interpretation schemes including VCA-IgA, EA-IgA and Rta-IgG in diagnosis of nasopharyngeal carcinoma. J Clin Otorhinolaryngol Head Neck Surgery. 2018;32(22):1740–4. https://doi.org/10.13201/j.issn.1001-1781.2018.22.014.CrossRef

58.

Zhang YN. The serum antibody Level changes of Rta-IgG/VCA-IgA and EA-IgA in nasopharyngeal carcinoma patients before and after radiation therapy. Univ South China. 2018;8:1–62.

59.

Cao S, Simons MJ, Qian C. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Clin Cancer. 2011;30(2):114–9. https://doi.org/10.5732/cjc.010.10377.CrossRef

60.

Puthavathana P, Kositanont U, Chongkolwatana C, Metheetrairut C, Chantarakul N, Nuntarakchaikul S, et al. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma. Asian Pac J Allergy Immunol. 1993;11(1):39–43. https://doi.org/10.1016/S0335-7457(05)80159-5.CrossRefPubMed

61.

Lam WKJ, Chan KCA, Lo YMD. Plasma Epstein-Barr virus DNA as an archetypal circulating tumor DNA marker. J Pathol. 2019;247(5):641–9. https://doi.org/10.1002/path.5249.CrossRefPubMedPubMedCentral

62.

Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999;59(21):5452–5.PubMed

63.

Han BL, Xu XY, Zhang CZ, et al. Systematic review on Epstein-Barr Virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev. 2012;13(6):2577–81. https://doi.org/10.7314/APJCP.2012.13.6.2577.CrossRefPubMed

64.

Li S, Deng Y, Li X, et al. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis. Chin Med J. 2010;123(9):1201–5. https://doi.org/10.3760/cma.j.issn.0366-6999.2010.09.018.CrossRefPubMed

65.

Cui ZL, Lin YY, Chen YS, Zheng YH, Chen Y. BRLF1 transcription activator IgG targeting Epstein-Barr virus hallmarks promising diagnostic efficacy in identification of nasopharyngeal carcinoma: a meta-analysis study. Int J Clin Exp Pathol. 2017;10(2):1113–21.

66.

Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36. https://doi.org/10.1148/radiology.143.1.7063747.CrossRefPubMed

67.

Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79(1):16–20. https://doi.org/10.1016/j.athoracsur.2004.09.040.CrossRefPubMed

68.

Qu H, Huang Y, Zhao S, Zhou Y, Lv W. Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. Eur Arch Otorhinolaryngol. 2020;277(1):9–18. https://doi.org/10.1007/s00405-019-05699-9.CrossRefPubMed

69.

Agsalda-Garcia M, Shieh T, Souza R, et al. Raman-enhanced spectroscopy (RESpect) probe for childhood non-hodgkin lymphoma. SciMedicine Journal. 2020;2(1):1–7. https://doi.org/10.28991/SciMedJ-2020-0201-1.CrossRefPubMedPubMedCentral

70.

King AD, Woo JKS, Ai QY, et al. Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. Ann Oncol. 2019;30(6):977–82. https://doi.org/10.1093/annonc/mdz106.CrossRefPubMed

71.

Gomez AML, Santana PC, Mourao AP, et al. Dosimetry study in head and neck of anthropomorphic phantoms in computed tomography scans. Sci Med J. 2020;2(1):38–43. https://doi.org/10.28991/SciMedJ-2020-0201-6.CrossRef

72.

Abdelaal AM, Attalla EM, Elshemey WM. Estimation of out-of-field dose variation using markus ionization chamber detector. Sci Med J. 2020;2(1):8–15. https://doi.org/10.28991/SciMedJ-2020-0201-2.CrossRef

73.

Tang JW, Rohwäder E, Chu IMT, Tsang RKY, Steinhagen K, Yeung ACM, et al. Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. J Clin Virol. 2007;40(4):284–8. https://doi.org/10.1016/j.jcv.2007.09.006.CrossRefPubMed

Title: The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis
Authors: Weixing Liu
Gui Chen
Xin Gong
Yingqi Wang
Yaoming Zheng
Xiao Liao
Wenjing Liao
Lijuan Song
Jun Xu
Xiaowen Zhang
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Epstein-Barr Virus
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-01862-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Elevated expression of MKRN3 in squamous cell carcinoma of the head and neck and its clinical significance

Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling

Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways

VWCE as a potential biomarker associated with immune infiltrates in breast cancer

Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer

Emerging roles of a pivotal lncRNA SBF2-AS1 in cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer